Disease progression, drug action and Parkinson’s disease: Why time cannot be ignored
Authors:
- 19 December 2007
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 64 (2) , 207-216
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's diseaseMovement Disorders, 2002
- The response to levodopa in parkinson's disease: Imposing pharmacological law and orderAnnals of Neurology, 1996
- The oxidant stress hypothesis in Parkinson's disease: Evidence supporting itAnnals of Neurology, 1992
- The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomaticAnnals of Neurology, 1992
- Kinetic‐dynamic relationship of oral levodopa: Possible biphasic response after sequential doses in Parkinson's diseaseMovement Disorders, 1992
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- Pharmacokinetic and Pharmacodynamic Modeling of L-DOPA Plasma Concentrations and Clinical Effects in Parkinsonʼs Disease After SinemetClinical Neuropharmacology, 1989
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981
- Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlationsJournal of the Neurological Sciences, 1973